Causes and Consequences of Snake Venom Variation.
Casewell NR, Jackson TNW, Laustsen AH, Sunagar K. · 2020
Read Causes and Consequences of Snake Venom Variation. by Casewell NR, Jackson TNW, Laustsen AH, Sunagar K. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7116101.txt.
Introduction
Casewell and co-authors review why snake venom differs so much between and within species, and what that means for bite victims, in Trends in Pharmacological Sciences. Snakebite strikes about 1.8 million people a year worldwide. Venom mixtures vary, and that variation can make standard antivenom fail.
New laboratory technologies now let researchers catalogue venom ingredients in full and trace how gene duplication and natural selection reshaped toxin families over time. Different toxin mixes produce different illnesses in victims, from bleeding to paralysis. The review closes with treatment designs meant to work across venom variants, aimed at the world's most lethal neglected tropical disease.
Catalog record
| CREATOR | Casewell NR, Jackson TNW, Laustsen AH, Sunagar K. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Causes and Consequences of Snake Venom Variation By Nicholas R Casewell, Timothy NW Jackson, Andreas H Laustsen, Kartik Sunaga Published in: Trends in pharmacological sciences DOI: 10.1016/j.tips.2020.05.006 ABSTRACT Abstract Snake venoms are mixtures of toxins that vary extensively between and within snake species. This variability has serious consequences for the management of the world’s 1.8 million annual snakebite victims. Advances in ‘omic’ technologies have empowered toxinologists to comprehensively characterize snake venom compositions, unravel the molecular mechanisms that underpin venom variation, and elucidate the ensuing functional consequences. In this review, we describe how such mechanistic processes have resulted in suites of toxin isoforms that cause diverse pathologies in human snakebite victims and we detail how variation in venom composition can result in treatment failure. Finally, we outline current therapeutic approaches designed to circumvent venom variation and deliver next-generation treatments for the world’s most lethal neglected tropical disease. SNAKE VENOM AND SNAKEBITE Venom is a remarkable evolutionary innovation found scattered across the animal tree of life [1]. Due to their diverse evolutionary histories and consequent variability, animal venoms have proven to be fascinating models for understanding a number of fundamental processes, including gene duplication, genotype-phenotype mapping, convergent evolution, and cell and tissue development [2–6], while the bioactivities of many toxins make them promising leads for the discovery of new human therapeutics [7]. The most well-studied venom systems are those of snakes. All ‘advanced snakes’ (superfamily: Colubroidea) have a pair of homologous oral venom glands located behind the eye on either side of the upper jaw [8,9]. These glands are connected to ducts that transfer the secreted venom to the base of morphologically diverse teeth that are often referred to as ‘fangs’. For many snakes, including those of greatest medical importance, these fangs are found at the front of the mouth, contain an enclosed venom canal, and are a highly efficient mechanism that facilitates the rapid injection of a bolus of venom. Although venomous snakes predominantly use their venom to assist with the acquisition of prey, they may also deploy it in defensive bites to deter potential predators and aggressors, including people. The consequences of such human snakebites can be severe. Current estimates suggest that venomous snakes cause up to 138 000 deaths worldwide each year and perhaps as many as 500 000 additional cases of venom-induced morbidity [10]. Snakebite envenomings predominantly affect the rural impoverished populations of the tropics and consequently the World Health Organization (WHO) has listed snakebite as a priority neglected tropical disease (NTD) (see Glossary)[11]. The pathological effects of snakebite are diverse and can include neuromuscular paralysis (neurotoxicity), hemorrhage and coagulopathy (hemotoxicity), and/or local swelling, blistering, and tissue necrosis (cytotoxicity) around the bite site [10]. These highly variable clinical signs are a direct consequence of variation in the toxin components found in venom; such variation can be extensive and occurs both inter- and intraspecifically [12–18].This variation also has a direct impact on the efficacy of snakebite treatments (antivenom), resulting in different antivenoms having to be manufactured against the venoms of distinct snake species [19]. GlossaryAntivenom:conventional snakebite therapies that consist of polyclonal antibodies purified from plasma/serum of equines/ovines hyperimmunized with snake venom/s.Aptamer:an oligonucleotide that binds to a specific target molecule. Cytotoxicity: the pathological consequences of venom cytotoxins acting predominantly at the region around the bite site, often resulting in swelling, blistering, and local tissue necrosis.Elapidae:a widely distributed, medically important, family of front-fanged venomous snakes ('elapids') that often cause systemic neurotoxicity and that includes cobras, mambas, kraits, coral snakes, taipans, and relatives.Hemotoxicity:the pathological consequences of venom hemotoxins acting on blood vessels and components of the coagulation cascade, often resulting in hypotension, systemic hemorrhage, and/or consumption coagulopathy.Multilocus gene family:a gene family consisting of multiple copies that have arisen due to recurrent tandem duplications of the ancestral gene.Nanobody:a single-domain antibody, typically of camelid origin, consisting of a single monomeric variable antibody domain (antibody fragment). Similar to a whole antibody, a nanobody can bind selectively to a specific antigen.Neglected tropical diseases (NTDs):a diverse group of communicable and noncommunicable diseases that are common in low-income populations of Africa, Asia, and the Americas. Neofunctionalization: the acquisition of a new protein function as the result of an accumulation of mutations in duplicated genes.Neurotoxicity:the pathological consequences of venom neurotoxins acting on neuromuscular junctions, often resulting in descending neuromuscular paralysis and respiratory failure.Neutral evolution:in molecular evolutionary terms, this is a mode of evolution where genes accumulate (nearly) equal proportions of synonymous (changes in nucleotides that do not alter the encoded amino acid residue) and nonsynonymous (changes in nucleotides that alter the coded amino acid) substitutions.Next-generation antivenom:future snakebite therapies that may consist of recombinantly expressed monoclonal antibodies, antibody fragments, alternative binding proteins, and/or small molecule inhibitors, as well as plasma/serum-derived antivenoms manufactured with the use of recombinant toxins (or fragments thereof) as immunogens.Nonsynonymous substitutions:mutations in the nucleotides that change the encoded amino acid.Peptide:a short chain of amino acids.Positive selection:also known as positive Darwinian selection, it is the force of natural selection that favors the accumulation of nonsynonymous substitutions over synonymous substitutions and results in the diversification of gene sequences across evolutionary time.Purifying selection:a force of natural selection thatfavors theaccumulationof synonymous substitutions over nonsynonymous substitutions, resulting in the conservation of gene sequences across evolutionary time.Recombinant antivenom:antivenom based on recombinantly expressed antibodies or antibody fragments. Recombinant antivenoms can comprise either monoclonal, oligoclonal, or polyclonal antibodies.Synonymous substitutions:changes at the nucleotide level that do not alter the resulting amino acid.Venomvariation:relative differences in the composition and/or abundance of toxins in the venoms of closely/distantly related animals or their geographically disparate populations.Viperidae:a widely distributed, medically important, family of frontfanged venomous snakes (‘vipers’) that often cause systemic hemotoxicity, and which includes pit vipers, vipers, adders, and relatives. Despite such complexity, recent advances in ‘omic’ technologies (e.g., proteomics, transcriptomics) have enabled the rapid characterization of the toxin components found in the venom of over 125 medically relevant species [20]. Here, we outline how this data has transformed our understanding of the processes that have generated snake venom variation and the consequences of such variation in the context of snakebite pathology and treatment. We also highlight how the rational application of venom composition data will enable the development of broadly effective therapies for snakebite envenoming, which is an essential step in mitigating the devastating effects this NTD inflicts upon the vulnerable victims of the tropics [21]. ECOLOGY DRIVES INTER- AND INTRASPECIFIC SNAKE VENOM VARIATION Venom is a functional trait used by one organism to interfere with the homeostatic processes of another, generally to facilitate feeding or deter predators or competitors [18]. Venom is therefore intrinsically ecological; a trait that mediates the outcome of interactions between two or more organisms [22]. ‘Venomous’ is not synonymous with ‘dangerous’, and the majority of venomous organisms, including snakes, pose no threat to humans, either because they rarely, if ever, envenom humans, or because the consequences of envenoming are trivial. Indeed, venom is a widespread trait amongst the ‘advanced snakes’, but almost all ‘medically important’ snakes (those capable of causing harm to humans via envenoming) are members of one of only three clades: the families Elapidae (cobras, mambas, sea snakes, taipans, and their relatives) and Viperidae (vipers and pit vipers, including adders, rattlesnakes, and their relatives) and the subfamily Atractaspidinae (mole vipers/stiletto snakes). As